Many companies have come forward over the last 2 years claiming they have treatments for COVID. And most of those claims have turned out to be nonsense. On the flip side, some companies have products that have been shown in human studies to be effective against COVID, and yet they’re prevented from informing the general public by restrictions imposed by regulatory bodies. One of those products appears to be NAD boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews):

Chromadex CEO Rob Fried at a Renmark investor event (@ 22:52 min mark):

Question:

“Has there been any more data released regarding the COVID-19 trial in Turkey that was using Niagen (Nicotinamide Riboside “NR” FAQs) as part of treatment for patients?”

CEO Rob Fried:

“When COVID hit, we did several things.

First thing we did was we said: “Look, if a virus attacks a cell, NAD must be involved”.

So, we did a dish study that showed that when a Coronavirus attaches to a cell, NAD levels decline by 80% within a few hours.

It’s intuitive that that would happen because the cell is trying to repel the virus — and in doing so, it will use NAD.

We then did a second dish study, where we put Nicotinamide Riboside “NR” (FAQs) (Reviews) in the solution — and we showed that it had a protective effect for the cell against the Coronavirus.

Then, a third study was done by a biotech company in Turkey on 100 symptomatic COVID patients where they gave them 2 grams a day of tru niagen (NR) plus 3 other vitamins.

And they showed a 24% reduction in time to recover.

And that would be considered a Phase 2 clinical study.

They published those results.

After that, the same group in Turkey, did a Phase 3 clinical on 300 patients.

But, in that study they showed a 39% reduction in time to recover for symptomatic COVID patients.

And it’s entirely intuitive.

If a virus penetrates a cell, the cell is either going to kill it OR it’s going to repel the virus.

And both of those processes require NAD.

So, by elevating NAD levels, it would make sense that the cell would be protected.

And that’s what the data showed.

And that’s the data that was published.

And that study has been peer reviewed and published.

Now, we issued a press release, and announced the results of that study.

But we got a letter from the FTC warning us, saying: “COVID is a disease. You’re a vitamin. You’re not a drug. You cannot publicize a therapeutic benefit to a disease with a vitamin. You have to apply for drug status”.

Since we’re not a drug, we had to take it down.

We don’t do any promotion.

We don’t do any marketing.

We don’t make anyone aware of it.

We don’t really do anything on the impact of tru niagen on viruses — specifically on COVID.

But, all of us take a great deal of it after reading the results of that study.

Now, we’ve also been informed by that same biotech company that performed that study that they applied for drug status in Turkey.

That happened about 6 or 7 months ago.

They applied for fast track drug approval status in Turkey for tru niagen (NR – FAQs) and 3 other vitamins — the cocktail — for therapeutic benefits for COVID patients.

And we’re awaiting results.

And we’ve not heard — other than the fact that it’s still an active process.

At this point, we don’t have additional news to report”

Related:

  • You can watch the full presentation here.
  • Could Vitamin Supplement Nicotinamide Riboside (NR) Alone Be the Driver of Expedited Recovery of Mild to Moderate COVID Patients in Recent Clinical Cocktail Studies? (Link)
  • Scientist Explains the NAD / NR / COVID Connection (Link)
  • Nicotinamide Riboside “NR” (FAQs) (Reviews)
  • Twitter: @RaisingNAD